NASDAQ : TVRD
Tvardi Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.863 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 11.51M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 9.20M | 8.74M | 4.46M | 2.80M | 2.73M |
| Research & Development | 18.01M | 18.01M | 23.65M | 15.87M | 18.47M |
| Operating Expenses | 27.20M | 26.75M | 28.11M | 18.66M | 21.19M |
| Operating Income | -27.20M | -26.75M | -28.11M | -18.66M | -21.19M |
| Interest Expense | -3.00K | ||||
| Interest & Investment Income | 1.14M | 1.38M | 747.00K | 1.32M | 654.00K |
| Other Non Operating Income (Expenses) | 7.16M | -2.04M | |||
| Pretax Income | -26.06M | -18.21M | -29.40M | -17.35M | -20.54M |
| Net Income | -26.06M | -18.21M | -29.40M | -17.35M | -20.54M |
| Net Income to Common | -26.06M | -18.21M | -29.40M | -17.35M | -20.54M |
| Shares Outstanding (Basic) | 9.40M | 7.42M | 2.57M | 6.38M | 6.37M |
| Shares Outstanding (Diluted) | 9.40M | 7.78M | 2.57M | 6.38M | 6.37M |
| EPS (Basic) | -2.77 | -2.46 | -11.42 | -2.72 | -3.22 |
| EPS (Diluted) | -2.77 | -3.26 | -11.42 | -2.72 | -3.22 |
| Free Cash Flow | -25.03M | -23.50M | -18.30M | -21.04M | -17.92M |
| Free Cash Flow Per Share | -2.66 | -3.02 | -7.11 | -3.30 | -2.81 |
| EBITDA | -27.11M | -26.65M | -28.01M | -18.57M | -21.11M |
| D&A For EBITDA | 95.00K | 95.00K | 95.00K | 95.00K | 85.00K |
| EBIT | -27.20M | -26.75M | -28.11M | -18.66M | -21.19M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 15.77M | 20.73M | 31.61M | 22.92M | 21.49M |
| Short-Term Investments | 10.08M | 22.25M | |||
| Cash & Short-Term Investments | 15.77M | 30.81M | 31.61M | 22.92M | 43.74M |
| Prepaid Expenses | 1.30M | 727.00K | 72.00K | 3.24M | 370.00K |
| Total Current Assets | 17.07M | 31.54M | 31.69M | 26.16M | 44.11M |
| Property, Plant & Equipment | 140.00K | 196.00K | 300.00K | 378.00K | 460.00K |
| Other Intangible Assets | 291.00K | 322.00K | 385.00K | 448.00K | 511.00K |
| Long-Term Deferred Charges | 2.81M | ||||
| Other Long-Term Assets | 17.00K | 17.00K | 17.00K | 17.00K | 17.00K |
| Total Assets | 17.52M | 32.07M | 35.20M | 27.00M | 45.10M |
| Accounts Payable | 4.64M | 3.22M | 2.19M | 1.61M | 2.41M |
| Accrued Expenses | 4.35M | 7.71M | 8.08M | 1.58M | 1.79M |
| Current Portion of Leases | 123.00K | 116.00K | 103.00K | 93.00K | 82.00K |
| Total Current Liabilities | 9.11M | 11.04M | 10.37M | 3.28M | 4.28M |
| Long-Term Debt | 30.26M | ||||
| Long-Term Leases | 22.00K | 85.00K | 201.00K | 275.00K | 368.00K |
| Total Liabilities | 9.13M | 11.13M | 40.83M | 3.56M | 4.64M |
| Common Stock | 9.00K | 9.00K | 2.00K | 19.00K | 19.00K |
| Additional Paid-In Capital | 132.08M | 131.38M | 1.10M | 762.00K | 446.00K |
| Retained Earnings | -123.71M | -110.45M | -92.24M | -62.84M | -45.49M |
| Comprehensive Income & Other | 8.00K | -24.00K | |||
| Total Common Equity | 8.38M | 20.95M | -91.13M | -62.06M | -45.05M |
| Shareholders' Equity | 8.38M | 20.95M | -5.63M | 23.45M | 40.45M |
| Total Liabilities & Equity | 17.52M | 32.07M | 35.20M | 27.00M | 45.10M |
| Total Debt | 145.00K | 201.00K | 30.56M | 368.00K | 450.00K |
| Net Cash (Debt) | 15.62M | 30.61M | 1.05M | 22.55M | 43.29M |
| Net Cash Per Share | 1.66 | 3.93 | 0.41 | 3.54 | 6.79 |
| Filing Date Shares Outstanding | 13.34M | 9.38M | 6.40M | 6.38M | 6.37M |
| Total Common Shares Outstanding | 9.38M | 9.38M | 6.40M | 6.38M | 6.37M |
| Working Capital | 7.96M | 20.50M | 21.32M | 22.88M | 39.83M |
| Book Value Per Share | 0.89 | 2.23 | -14.24 | -9.73 | -7.07 |
| Tangible Book Value | 8.09M | 20.62M | -91.52M | -62.51M | -45.56M |
| Tangible Book Value Per Share | 0.86 | 2.20 | -14.30 | -9.80 | -7.15 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -26.06M | -18.21M | -29.40M | -17.35M | -20.54M |
| Depreciation & Amortization | 95.00K | 95.00K | 95.00K | 95.00K | 85.00K |
| Loss (Gain) From Sale of Investments | -108.00K | -200.00K | -194.00K | -355.00K | |
| Stock-Based Compensation | 1.40M | 1.40M | 319.00K | 314.00K | 246.00K |
| Other Operating Activities | 77.00K | -7.09M | 2.04M | 51.00K | 34.00K |
| Change in Accounts Payable | -1.15M | 919.00K | 5.57M | -1.01M | 2.19M |
| Change in Other Net Operating Assets | 723.00K | -411.00K | 3.07M | -2.95M | 471.00K |
| Operating Cash Flow | -25.03M | -23.50M | -18.30M | -21.04M | -17.87M |
| Capital Expenditures | -50.00K | ||||
| Investment in Securities | 20.47M | -10.08M | 22.47M | -21.95M | |
| Investing Cash Flow | 20.47M | -10.08M | 22.47M | -22.00M | |
| Long-Term Debt Issued | 28.30M | ||||
| Net Debt Issued (Repaid) | 28.30M | ||||
| Issuance of Common Stock | 108.00K | 532.00K | 5.00K | 2.00K | 4.00K |
| Other Financing Activities | -429.00K | 22.17M | -1.30M | ||
| Financing Cash Flow | -321.00K | 22.70M | 27.00M | 2.00K | 4.00K |
| Net Cash Flow | -4.88M | -10.88M | 8.70M | 1.43M | -39.86M |
| Free Cash Flow | -25.03M | -23.50M | -18.30M | -21.04M | -17.92M |
| Free Cash Flow Per Share | -2.66 | -3.02 | -7.11 | -3.30 | -2.81 |
| Levered Free Cash Flow | -16.26M | -15.22M | -6.91M | -15.13M | |
| Unlevered Free Cash Flow | -16.26M | -15.22M | -6.91M | -15.13M | |
| Change in Working Capital | -427.00K | 508.00K | 8.64M | -3.96M | 2.67M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 10.67M | 40.34M | |||
| Enterprise Value | -4.95M | 4.11M | |||
| Last Close Price | 0.79 | 4.30 | |||
| PB Ratio | 0.89 | 1.93 | |||
| P/TBV Ratio | 1.35 | 1.96 | |||
| Debt / Equity Ratio | 0.02 | 0.01 | -5.43 | 0.02 | 0.01 |
| Net Debt / Equity Ratio | -1.86 | -1.46 | 0.19 | -0.96 | -1.07 |
| Net Debt / EBITDA Ratio | 0.58 | 1.15 | 0.04 | 1.21 | 2.05 |
| Net Debt / FCF Ratio | 0.62 | 1.30 | 0.06 | 1.07 | 2.42 |
| Quick Ratio | 1.73 | 2.79 | 3.05 | 6.99 | 10.23 |
| Current Ratio | 1.87 | 2.86 | 3.06 | 7.97 | 10.31 |
| Return on Equity (ROE) | -126.18% | -237.81% | -329.99% | -54.30% | |
| Return on Assets (ROA) | -55.51% | -49.70% | -56.48% | -32.36% | |
| Return on Capital Employed (ROCE) | -323.70% | -127.20% | -113.20% | -78.70% | -51.90% |
| Earnings Yield | -346.72% | -45.15% | |||
| FCF Yield | -229.98% | -58.25% | |||
| Buyback Yield / Dilution | -134.87% | -202.35% | 59.64% | -0.09% |